Evidence map›Paper›PMID 29078136›Full record

ReviewBiomaterials2018

Bioengineering a non-genotoxic vector for genetic modification of mesenchymal stem cells.

Xuguang Chen, Alireza Nomani, Niket Patel, Faranak S Nouri, Arash Hatefi

Abstract readReview
In one paragraph

Review in Biomaterials, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xuguang ChenDepartment of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Alireza NomaniDepartment of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Niket PatelDepartment of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Faranak S NouriDepartment of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Arash HatefiDepartment of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ, 08854, USA. Electronic address: ahatefi@pharmacy.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian CancerR01CA175318 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI HATEFI, ARASH · 2015 to 2019
$1.8M
Bioengineering a Safe and Efficient Vector Technology for Stem Cell TransfectionR21EB016792 · NIBIB · RUTGERS, THE STATE UNIV OF N.J. · PI HATEFI, ARASH · 2014 to 2015
$426k
NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA175318NIBIB NIH HHS R21 EB016792
6 · The paper itself

Abstract

Vectors used for stem cell transfection must be non-genotoxic, in addition to possessing high efficiency, because they could potentially transform normal stem cells into cancer-initiating cells. The objective of this research was to bioengineer an efficient vector that can be used for genetic modification of stem cells without any negative somatic or genetic impact. Two types of multifunctional vectors, namely targeted and non-targeted were genetically engineered and purified from E. coli. The targeted vectors were designed to enter stem cells via overexpressed receptors. The non-targeted vectors were equipped with MPG and Pep1 cell penetrating peptides. A series of commercial synthetic non-viral vectors and an adenoviral vector were used as controls. All vectors were evaluated for their efficiency and impact on metabolic activity, cell membrane integrity, chromosomal aberrations (micronuclei formation), gene dysregulation, and differentiation ability of stem cells. The results of this study showed that the bioengineered vector utilizing VEGFR-1 receptors for cellular entry could transfect mesenchymal stem cells with high efficiency without inducing genotoxicity, negative impact on gene function, or ability to differentiate. Overall, the vectors that utilized receptors as ports for cellular entry (viral and non-viral) showed considerably better somato- and genosafety profiles in comparison to those that entered through electrostatic interaction with cellular membrane. The genetically engineered vector in this study demonstrated that it can be safely and efficiently used to genetically modify stem cells with potential applications in tissue engineering and cancer therapy.

Indexed as

Gene Transfer TechniquesAdipose TissueBioengineeringCell DifferentiationCell-Penetrating PeptidesCell ProliferationCells, CulturedErb-b2 Receptor Tyrosine KinasesEscherichia coliHumansMesenchymal Stem CellsNanoparticlesParticle SizePeptides, CyclicSurface PropertiesVascular Endothelial Growth Factor Receptor-1Cell-Penetrating Peptidescyclic peptide 24-41CErb-b2 Receptor Tyrosine KinasesPeptides, CyclicVascular Endothelial Growth Factor Receptor-1Cell transfectionGenotoxicityNanoparticlesNon-viralStem cellsVector engineering

Identifiers

PMID29078136
PMCPMC5671363
OpenAlexW2765510193

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.